Frazier Life Sciences Acquisition Corp. II is a newly organized blank check company incorporated on August 7, 2026, as a Cayman Islands exempted company with limited liability for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to throughout this prospectus as our initial business combination. To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We have generated no operating revenues to date and we do not expect that we will generate operating revenues until we consummate our initial business combination. While we may pursue an initial business combination opportunity in any business, industry, sector or geographical location, we intend to capitalize on the experience and ability of our management team to identify promising opportunities in the biotechnology sector, with the goal of financing a company that can develop important new therapies for patients while creating value for shareholders. Our sponsor is Frazier Life Sciences Holdings II LLC, an affiliate of Frazier Life Sciences Management, L.P. (“FLS”). FLS originated as part of Frazier Healthcare Partners, which was founded in 1991 and combined healthcare growth buyout and life sciences strategies as one of the first healthcare-dedicated investment firms. The life sciences strategy was separated into dedicated funds and decision-making in 2005 and became a separate management company and legal entity in 2022. Today, FLS invests across venture capital and public equity strategies, with dedicated funds for each. Our executive offices are located in Palo Alto, California.
Read More on Frazier Life Sciences Acquisition Corp. II
